Steglatro recommended for usage on UK's NHS in type 2 diabetes

27 March 2019

The UK's National Institute of Care and Health Excellence (NICE) has issued a final appraisal determination (FAD) recommending Steglatro as a monotherapy in British adults with type 2 diabetes (T2DM) for whom metformin is contraindicated or not tolerated, or as part of a dual therapy with metformin.

This means that the sodium-glucose cotransporter-2 (SGLT-2) inhibitor will be made routinely available in this indication within Britain's National Health Service.

Steglatro, from US pharma giant Merck & Co (NYSE: MRK), a company known as MSD outside North America, is a therapy that has demonstrated effective glycemic control and reductions in blood pressure and weight that are comparable to other SGLT-2 inhibitors, but it has a 20% lower acquisition cost than its competitors.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK